| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-12-1803 |
| P698 | PubMed publication ID | 22962441 |
| P2093 | author name string | Francisco Borrego | |
| Edvardas Kaminskas | |||
| Haleh Saber | |||
| Julie Bullock | |||
| Kathleen Clouse | |||
| Marjorie Shapiro | |||
| Richard Pazdur | |||
| Xiao Hong Chen | |||
| Janice Brown | |||
| Robert Kane | |||
| Ann Farrell | |||
| Yanli Ouyang | |||
| Kyung Lee | |||
| R Angelo de Claro | |||
| Aakanksha Khandelwal | |||
| Kallappa Koti | |||
| Bahru Habtemariam | |||
| Virginia Kwitkowski | |||
| Mark Rothmann | |||
| Karen McGinn | |||
| Lara Akinsanya | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug approval | Q42214612 |
| Hodgkin lymphoma | Q209369 | ||
| P304 | page(s) | 5845-5849 | |
| P577 | publication date | 2012-09-07 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. | |
| P478 | volume | 18 |
| Q36207446 | 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma |
| Q28487973 | A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma |
| Q48165994 | A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo |
| Q47217500 | A novel enediyne-integrated antibody-drug conjugate shows promising anti-tumor efficacy against CD30+ lymphomas |
| Q92147359 | A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia |
| Q38445336 | Achieving incompatible transplantation through desensitization: current perspectives and future directions |
| Q38808823 | Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer |
| Q91622958 | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma |
| Q53739135 | Antibody-Drug Conjugates for Cancer Therapy. |
| Q38489049 | Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability |
| Q93068497 | Antibody-drug conjugates for cancer |
| Q38864720 | Antibody-drug conjugates for cancer therapy. |
| Q38665425 | Antibody-mediated delivery of therapeutics for cancer therapy. |
| Q64080022 | Antiproliferative Effects of the Natural Oxadiazine Nocuolin A Are Associated With Impairment of Mitochondrial Oxidative Phosphorylation |
| Q46522736 | Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper |
| Q38557519 | Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates |
| Q36824455 | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer |
| Q47098861 | Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines |
| Q38476250 | Brentuximab vedotin for the treatment of Hodgkin's lymphoma |
| Q34325201 | Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma |
| Q43602716 | Brentuximab vedotin: the science of common sense |
| Q57471771 | CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells |
| Q35691210 | CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin |
| Q47416235 | CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration |
| Q38138482 | CD30 as a therapeutic target for lymphoma |
| Q42199195 | CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia |
| Q37098844 | CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma |
| Q47423347 | Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. |
| Q92509415 | Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q40162651 | Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma. |
| Q30240160 | Diagnostic, prognostic and therapeutic role of CD30 in lymphoma |
| Q28068341 | Discovery of Anticancer Agents of Diverse Natural Origin |
| Q41573147 | Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma. |
| Q38196943 | Emerging drugs for T-cell lymphoma |
| Q39259769 | FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma |
| Q44814876 | HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. |
| Q34718363 | Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. |
| Q45913193 | Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. |
| Q50921086 | Human MAP Tau Based Targeted Cytolytic Fusion Proteins |
| Q38545545 | Ibrutinib in B lymphoid malignancies |
| Q36797398 | Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. |
| Q38992200 | Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era |
| Q38759986 | Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma |
| Q38154186 | Industrial natural product chemistry for drug discovery and development. |
| Q38781439 | KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma |
| Q92495346 | Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets |
| Q38714213 | Merocyclophanes C and D from the Cultured Freshwater Cyanobacterium Nostoc sp. (UIC 10110). |
| Q34655256 | Microtubule inhibitor-based antibody-drug conjugates for cancer therapy |
| Q38206275 | Monoclonal antibodies as therapeutics in human malignancies |
| Q47159035 | Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy |
| Q39815639 | New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats |
| Q38581830 | Novel agents for the treatment of Hodgkin lymphoma |
| Q41728703 | Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. |
| Q35168766 | Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses |
| Q42550983 | Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event |
| Q39193590 | Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma |
| Q58088020 | Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study |
| Q64117043 | Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review |
| Q38131563 | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates |
| Q34802443 | Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? |
| Q36264723 | Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. |
| Q36534677 | Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis |
| Q38664909 | Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. |
| Q28553497 | Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics |
| Q52676610 | Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers. |
| Q37412853 | Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin |
| Q33875604 | The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model |
| Q38513816 | The new therapeutical scenario of Hodgkin lymphoma |
| Q64099738 | The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q52948835 | Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. |
| Q34316400 | What's fueling the biotech engine-2011 to 2012. |
| Q54006284 | [Progress on allogeneic hematopoietic stem cell transplantation in peripheral T cell lymphoma]. |
Search more.